Discover
CRGX
CARGO Therapeutics, Inc.
4.47
undefined x undefined
undefined x undefined
bid
ask
+
0.00
0.00%
04:00 PM
| Ytd | ||
| 1y |
4.47
day range
4.47
12.17
52 week range
33.92
| Open | 4.53 | Prev Close | 4.47 | Low | 4.47 | High | 4.47 | Mkt Cap | 677.53M |
| Vol | 9.53M | Avg Vol | 224.14K | EPS | -17.59 | P/E | N/A | Forward P/E | -3.16 |
| Beta | N/A | Short Ratio | 28.85 | Inst. Own | 109.63% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 18.56 | 200-d Avg | 19.11 | 1yr Est | 31.71 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-12 | 2024-09 | -1.14 | -0.88 | 0.26 | 22.81% |
| 2024-08-12 | 2024-06 | -1.06 | N/A | N/A | N/A |
| 2024-08-12 | 2024-06 | -1.06 | -1.02 | 0.04 | 3.77% |
| 2024-05-14 | 2024-03 | -1.05 | N/A | N/A | N/A |
| 2024-05-14 | 2024-03 | -1.05 | -0.87 | 0.18 | 17.14% |
| 2024-03-21 | 2023-12 | -1.62 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-26 | William Blair | Upgrade | Outperform | |
| 2024-11-15 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-11-13 | Chardan Capital | Upgrade | Buy | Buy |
| 2024-08-13 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-08-13 | Piper Sandler | Upgrade | Overweight | Overweight |
| 2024-07-22 | HC Wainwright & Co. | Upgrade | Buy |
Profile
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-09-18 | CHAPMAN GINA | Chief Executive Officer | 103.91K | Sale |
| 2023-11-13 | PERCEPTIVE ADVISORS, L.L.C. | Unknown | 0.00 | Purchase |
| 2024-09-17 | RADHAKRISHNAN ANUP | Chief Financial Officer | 6.45K | Sale |
| 2024-05-29 | SAMSARA BIOCAPITAL GP, LLC | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2023-11-13 | THIRD ROCK VENTURES V, L.P. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2023-11-13 | WELLINGTON BIOMEDICAL INNOVATION MASTER INVESTORS CAYMAN II | Beneficial Owner of more than 10% of a Class of Security | 737.00K | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | FMR, LLC | 6.95M | 102.37M | 15.11% |
| 2024-09-29 | Samsara BioCapital, LLC | 4.42M | 65.00M | 9.59% |
| 2024-09-29 | RTW Investments LP | 4.10M | 60.34M | 8.91% |
| 2024-09-29 | Perceptive Advisors Llc | 3.68M | 54.21M | 8.00% |
| 2024-09-29 | Price (T.Rowe) Associates Inc | 2.69M | 39.66M | 5.85% |
| 2024-09-29 | Janus Henderson Group PLC | 2.68M | 39.38M | 5.81% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Price (T.Rowe) Health Sciences Fund | 1.30M | 19.12M | 2.82% |
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 1.20M | 17.66M | 2.61% |
| 2024-10-30 | Fidelity Select Portfolios - Health Care | 995.81K | 14.66M | 2.16% |
| 2024-10-30 | iShares Russell 2000 ETF | 872.28K | 12.84M | 1.90% |
| 2024-09-29 | Price (T.Rowe) New Horizons Fund | 701.82K | 10.33M | 1.52% |
| 2024-08-30 | Fidelity Small Cap Growth Fund | 638.53K | 9.40M | 1.39% |